A Randomized Controlled Trial of Dual-plasmid HBV DNA Vaccine Mediated by in Vivo Electroporation in Chronic Hepatitis B Patients Under Lamivudine Chemotherapy
In order to study the immunotherapeutic effects of electroporation (EP)-mediated dual-plasmids Hepatitis B Virus DNA vaccine, the investigators plan to conduct a double-blind, randomized, placebo-controlled trial, approved by Chinese State Food and Drug Administration with written informed consent from each chronic hepatitis B (CHB) patients with baseline ALT more than 2 times the ULN, for whom antiviral treatment is indicated and who were under the simultaneous lamivudine (LAM) chemotherapy.
开始日期2011-09-01
申办/合作机构-
100 项与 治疗性双质粒HBV DNA疫苗(Guangzhou Baiyunshan Bai Di Bio-technology) 相关的临床结果
登录后查看更多信息
100 项与 治疗性双质粒HBV DNA疫苗(Guangzhou Baiyunshan Bai Di Bio-technology) 相关的转化医学
登录后查看更多信息
100 项与 治疗性双质粒HBV DNA疫苗(Guangzhou Baiyunshan Bai Di Bio-technology) 相关的专利(医药)
登录后查看更多信息
100 项与 治疗性双质粒HBV DNA疫苗(Guangzhou Baiyunshan Bai Di Bio-technology) 相关的药物交易